POSTER SESSION V Wednesday, March 10, 2004   —  9:30 AM - 12:00 Noon EXHIBIT HALL B and C DERMATOPATHOLOGY 66 "Animal Type Melanoma" - A Clinicopathologic Study of 15 Cases (363) FC Antony, AS Trelles, E Calonje - St. Thomas' Hospital, London, United Kingdom; Carlos Haya Hospital, Malaga, Spain; St. Thomas' Hospital, London, United Kingdom 67 Cutaneous Desmoplastic Melanomas Are Clinically and Histologically Different from Spindle Cell Melanomas, NOS (367) I Boiko, V Goncharuk, M Cohn, AH Diwan, JE Gershenwald, VG Prieto - UT-Medical School, Houston, TX; UT-M.D.Anderson Cancer Center, Houston, TX 68 Immunoreactivity of CD99 in Invasive Malignant Melanoma (381) MA Glasgow, AE Wilkerson, KM Hiatt - University of Arkansas for Medical Sciences, Little Rock, AR 69 Classification of Melanoma by Functional Genomics: Distinction of Primary Cutaneous Desmoplastic Melanoma from Non-Desmoplastic Melanoma by Gene Expression Profiling (370) KJ Busam, H Zhao, A Viale, D Coit, A Houghton - Memorial Sloan-Kettering Cancer Center, New York, NY 70 Vascular Endothelial Growth Factor Is an Unfavorable Prognostic Factor in 1.5-to 3.00 mm Breslow Depth Melanomas (384) M Idoate, P Redondo, MD Lozano, A Panizo, J Echeveste, J Pardo - University of Navarra, Pamplona, Navarra, Spain 71 Distinctive VEGF-c and Microvessel Profiles by Topographic Compartments Characterize Spitz Tumors (383) E Husain, L Pozo-Garcia, A Blanes, SJ Diaz-Cano - Barts and the London Hospitals, London, England, United Kingdom; University of Malaga School of Medicine, Malaga, Spain 72 Constitutive Activation of Stat3 and Stat5 in Melanocytic Lesions (411) H Wang, H Wang, SS Shen, GN Fuller, W Zhang, H Diwan, VG Prieto - The University of Texas M. D. Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX 73 Regulation of the Cell Cycle by Hypoxia in Malignant Melanoma (396) MJ Murphy, M Keough, JA Carlson, KP Claffey - University of Connecticut Health Center, Farmington, CT; Albany Medical Center, Albany, NY 74 Analysis of BRAF Gene Mutation in Primary Cutaneous Melanomas and Nevi (371) HM Chen, M Tretiakova, M Stratton, C Shea, M Medenica, T Krausz - New York University School of Medicine, New York, NY; The University of Chicago Hospitals, Chicago, IL; Wellcome Trust Sanger Institute, Cambridge, United Kingdom 75 Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) in Common and Atypical Nevi, and Primary Cutaneous Melanoma (409) P Uribe, II Wistuba, ML Perez-Cotapos, S Gonzalez - Catholic University of Chile, School of Medicine 76 BRAF Mutation In Melanoma and Nevi Is Not Attributable to Defective DNA Mismatch Repair (407) P Uribe, II Wistuba, S Gonzalez - Catholic University of Chile, School of Medicine, Santiago, Chile 77 Microsatellite Instability (MSI) and Loss of Heterozigosity (LOH) in Pediatric Melanoma (408) P Uribe, II Wistuba, ML Perez-Cotapos, S Gonzalez - Catholic University of Chile, School of Medicine, Santiago, Chile 78 Nuclear and Cytoplasmic Expression of the DNA-Repairing and Anti-Apoptotic Ku-70 in Melanocytic Neoplasms (366) C Bengana, VG Prieto, P Zhang, AH Diwan - UT-MD Anderson Cancer Center, Houston, TX 79 Expression of Peroxisome Proliferator-Activated Receptor g in Melanocytic Lesions of the Skin (402) JA Ramirez, R Gupta, MS Rao, LK Diaz - Feinberg School of Medicine, Northwestern Univ., Chicago, IL 80 CXCR3 Chemokine Receptor Immunoreactivity in Primary Cutaneous Malignant Melanoma (395) C Monteagudo, JM Martin, E Jorda, A Llombart-Bosch - Hospital Clinico Universitario. University of Valencia, Valencia, Spain 81 Promoter Hypermethylation of the Ataxia-Telangiectasia-Mutated (ATM) Gene in Benign and Malignant Melanocytic Lesions of the Skin (374) W Clingan, L Li, X Su, C-Y Fan, BR Smoller - University of Arkansas for Medical Sciences and John L. McClellan Memorial Veterans Hospital, Little Rock, AR 82 Does the Pathologist Have a Role in Confirming That a Node Submitted as Sentinel Is Truly Sentinel? (382) R Huang, D-R Wen, E Itakura, RR Turner, AJ Cochran - University of California at Los Angeles, Los Angeles, CA; John Wayne Cancer Institute at St.John's Health Center, Santa Monic, CA 83 Is Sentinel Node Susceptibility to Metastases Influenced by Tumor-Derived Cytokines? RT in situ PCR Studies (385) E Itakura, R Huang, D Wen, A Cochran - University of California Los Angeles, Los Angeles, CA 84 Evaluation of Melanoma Non-Sentinel Nodes: How Much Is Enough? (412) DR Wen, RR Huang, S Binder, DL Morton, AJ Cochran - University of California, Los Angeles, Los Angeles, CA; John Wayne Cancer Institute, Santa Monica, CA 85 Lentigo Maligna: The Dermatopathologic Effects of Topical Imiquimod Therapy (375) AN Crowson, S Metcalf, M Naylor, CM Magro, R Haque, C Garcia, RL Cornelison - University of Oklahoma, Tulsa, OK; Regional Medical Laboratory, Tulsa, OK; Ohio State University Medical Center, Columbus, OH